Number and percentage of adults and children enrolled in HIV carea and eligible for co-trimoxazole prophylaxis (according to national guidelines) currently receiving co-trimoxazole prophylaxis

Export Indicator

Number and percentage of adults and children enrolled in HIV carea and eligible for co-trimoxazole prophylaxis (according to national guidelines) currently receiving co-trimoxazole prophylaxis
What it measures

WHO recommends
administration of co-trimoxazole for the following groups: adults living with HIV, including pregnant
women, children living with HIV and infants exposed to HIV.b The WHO guidelines offer countries a
choice of whether to provide co-trimoxazole broadly or according to disease stage.

Rationale

Co-trimoxazole prophylaxis is a simple and cost-effective intervention that reduces the risk of
opportunistic infections and mortality among children and adults living with HIV.

Numerator

Number of adults and children living with HIV enrolled in HIV carea and receiving co-trimoxazole prophylaxis

Denominator

A. Number of adults and children living with HIV enrolled in HIV care who are eligible for
co-trimoxazole prophylaxis based on national guidelines. B. Estimated number of people living with HIV
in the country

Calculation

Numerator / Denominator

Method of measurement

Numerator: Individuals should be considered to be “receiving” co-trimoxazole prophylaxis if co-
trimoxazole has been prescribed and obtained by the patient (provided by a program or procured by the
patient). Include “active” patients: ones seen at the clinic at least once in the past year. Do not include
HIV-exposed infants who have not yet been confirmed as HIV positive and are therefore not enrolled in
HIV care. The indicator is not meant to account for short-term lapses in adherence or short-term stock-
outs. If individuals are served by more than one program that might provide co-trimoxazole prophylaxis,
the figure should be adjusted as needed so that the numerator represents only unique individuals
receiving co-trimoxazole within the reporting period.
Countries should focus on compiling data for the numerator from patient registers at facilities. Where
patient level data are not available, countries may develop program or facility-level estimates of coverage with co-trimoxazole and apply these estimates to the total number of individuals receiving care and support services through those programs or facilities. People living with HIV receiving co-trimoxazole in both the private sector and the public sector should be included in the numerator where data for both
are available.

Denominator: (A) Number of people living with HIV eligible for co-trimoxazole according to national
guidelines. This denominator will be derived through estimations based on country guidelines for co-
trimoxazole (where guidelines exist). The proportion derived from using this denominator will provide
data on the coverage of co-trimoxazole among people living with HIV eligible to receive co-trimoxazole.
(B) Estimated number of people living with HIV in the country. The denominator is an estimation
of the number of people living with HIV produced through the SPECTRUM model, which is based on
surveillance data from facilities and calibrated as new population-based survey data become available.
The proportion derived from using this denominator will provide country coverage data of co-
trimoxazole among people living with HIV.

Disaggregation: By sex and age
Age represents an individual’s age at the end of the reporting period or when last seen at the facility.

Measurement frequency

Continuously

Disaggregation

Condom type: N/A

Education: N/A

Gender: Male, Female

Geographic location: N/A

HIV status: N/A

Pregnancy status: N/A

Sector: N/A

Service Type: N/A

Target: N/A

Time period: N/A

Type of orphan: N/A

Type/Timing of testing: N/A

Vulnerability status: N/A

Explanation of the numerator
Explanation of the denominator
Strengths and weaknesses
Further information